Search Results - "EISERMANN, Mona"

  • Showing 1 - 10 results of 10
Refine Results
  1. 1
  2. 2
  3. 3

    Preclinical Toxicological Assessment of A Novel siRNA, SLN360, Targeting Elevated Lipoprotein (a) in Cardiovascular Disease by Rider, David, Chivers, Simon, Aretz, Julia, Eisermann, Mona, Löffler, Kathrin, Hauptmann, Judith, Morrison, Eliot, Campion, Giles

    Published in Toxicological sciences (24-09-2022)
    “…Abstract SLN360 is a liver-targeted N-acetyl galactosamine (GalNAc)-conjugated small interfering RNA (siRNA) with a promising profile for addressing…”
    Get full text
    Journal Article
  4. 4

    Pre-clinical assessment of SLN360, a novel siRNA targeting LPA, developed to address elevated lipoprotein (a) in cardiovascular disease by Rider, David A., Eisermann, Mona, Löffler, Kathrin, Aleku, Manuela, Swerdlow, Daniel I., Dames, Sibylle, Hauptmann, Judith, Morrison, Eliot, Lindholm, Marie Wikström, Schubert, Steffen, Campion, Giles

    Published in Atherosclerosis (01-05-2022)
    “…The LPA gene encodes apolipoprotein (a), a key component of Lp(a), a potent risk factor for cardiovascular disease with no specific pharmacotherapy. Here we…”
    Get full text
    Journal Article
  5. 5
  6. 6

    Therapeutic Small Interfering RNA Targeting Complement C3 in a Mouse Model of C3 Glomerulopathy by Zanchi, Cristina, Locatelli, Monica, Cerullo, Domenico, Aumiller, Verena, Corna, Daniela, Rottoli, Daniela, Eisermann, Mona, Donadelli, Roberta, Mousavi, Mansoureh, Noris, Marina, Remuzzi, Giuseppe, Benigni, Ariela, Zoja, Carlamaria

    Published in The Journal of immunology (1950) (01-04-2022)
    “…Alternative pathway complement dysregulation with abnormal glomerular C3 deposits and glomerular damage is a key mechanism of pathology in C3 glomerulopathy…”
    Get full text
    Journal Article
  7. 7

    Abstract 14720: Pre-clinical Safety Assessment of SLN360, a Novel Short Interfering Ribonucleic Acid Targeting LPA by Rider, David, Swerdlow, Daniel, Eisermann, Mona, Loeffler, Kathrin, Hauptmann, Judith, Morrison, Eliot, Wikstrom Lindholm, Marie, Schubert, Steffen, Campion, Giles

    Published in Circulation (New York, N.Y.) (17-11-2020)
    “…IntroductionSLN360 is a liver-targeted N-acetyl galactosamine (GalNAc)-conjugated siRNA with a promising profile for addressing Lp(a)-related cardiovascular…”
    Get full text
    Journal Article
  8. 8
  9. 9

    Targeting Protein S Using Small Interfering RNA Is Well Tolerated and Protects Mice with Hemophilia a from Acute Hemarthrosis by Prince, Raja Eladnani, Schaeper, Ute, Dames, Sibylle, Calzavarini, Sara, Quarroz, Claudia, Reina Caro, Maria Desiré, Chanfon Bätzner, Astrid, Löffner, Kathrin, Eisermann, Mona, Angelillo-Scherrer, Anne

    Published in Blood (05-11-2020)
    “…Introduction & Aim: Hemophilia A (HA) is an X-linked disorder caused by an absence or a reduction of coagulation factor VIII. Patients with HA often suffer…”
    Get full text
    Journal Article
  10. 10

    Abstract 9538: A Novel Short Interfering Ribonucleic Acid Shows Potent and Sustained Reduction of Serum Lipoprotein (a) in Cynomolgus Monkeys by Aleku, Manuela, Eisermann, Mona, Löffler, Kathrin, Dames, Sibylle, Frauendorf, Christian, Wikstrom Lindholm, Marie, Schubert, Steffen, Rider, David

    Published in Circulation (New York, N.Y.) (19-11-2019)
    “…IntroductionSLN360 is a liver targeted GalNAc-conjugated siRNA developed for the treatment of cardiovascular disorders associated with elevated Lp(a). Lp(a) is…”
    Get full text
    Journal Article